SPRY vs. ABVX, OCUL, IMNM, ARQT, OPK, PRAX, ETNB, TYRA, SAVA, and ALXO
Should you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include ABIVAX Société Anonyme (ABVX), Ocular Therapeutix (OCUL), Immunome (IMNM), Arcutis Biotherapeutics (ARQT), OPKO Health (OPK), Praxis Precision Medicines (PRAX), 89bio (ETNB), Tyra Biosciences (TYRA), Cassava Sciences (SAVA), and ALX Oncology (ALXO). These companies are all part of the "pharmaceutical preparations" industry.
ABIVAX Société Anonyme (NASDAQ:ABVX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings.
ABIVAX Société Anonyme has higher earnings, but lower revenue than ARS Pharmaceuticals.
In the previous week, ARS Pharmaceuticals had 6 more articles in the media than ABIVAX Société Anonyme. MarketBeat recorded 10 mentions for ARS Pharmaceuticals and 4 mentions for ABIVAX Société Anonyme. ARS Pharmaceuticals' average media sentiment score of 1.66 beat ABIVAX Société Anonyme's score of 0.30 indicating that ABIVAX Société Anonyme is being referred to more favorably in the media.
ARS Pharmaceuticals received 6 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. Likewise, 71.43% of users gave ARS Pharmaceuticals an outperform vote while only 66.67% of users gave ABIVAX Société Anonyme an outperform vote.
ABIVAX Société Anonyme currently has a consensus price target of $32.00, suggesting a potential upside of 127.11%. ARS Pharmaceuticals has a consensus price target of $18.50, suggesting a potential upside of 111.67%. Given ARS Pharmaceuticals' higher possible upside, equities analysts clearly believe ABIVAX Société Anonyme is more favorable than ARS Pharmaceuticals.
47.9% of ABIVAX Société Anonyme shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 35.6% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
ARS Pharmaceuticals' return on equity of 0.00% beat ABIVAX Société Anonyme's return on equity.
Summary
ARS Pharmaceuticals beats ABIVAX Société Anonyme on 7 of the 11 factors compared between the two stocks.
Get ARS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ARS Pharmaceuticals Competitors List
Related Companies and Tools
